4837 Amber Valley Parkway
Suite 11
Fargo, ND 58104
United States
701 353 0022
http://www.immunoprecise.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. James S. Kuo M.B.A., M.D. | Independent Chairman | N/A | N/A | 1965 |
Dr. Jennifer Lynne Bath Ph.D. | CEO, Pres & Director | 1.06M | N/A | N/A |
Ms. Lisa Helbling | Chief Financial Officer | 438.46k | N/A | N/A |
Dr. Yasmina Noubia Abdiche Ph.D. | Chief Scientific Officer | 30.49k | N/A | N/A |
Dr. Stefan Lang | Chief Bus. Officer | 219.58k | N/A | N/A |
Mr. David E. Orton | Chief Operating Officer | N/A | N/A | N/A |
Ms. Lauren Smith | VP of Marketing and Sales | N/A | N/A | N/A |
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
ImmunoPrecise Antibodies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.